June 18, 2010 Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th

First Page		Document Content
Date: 2010-06-17 22:05:31 Overactive bladder Muscarinic antagonists Astellas Pharma Solifenacin Urinary incontinence Frequent urination Urge incontinence Urination Percutaneous tibial nerve stimulation Medicine Urology Incontinence		June 18, 2010 Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th Add to Reading List Source URL: www.astellas.com Download Document from Source Website File Size: 41,04 KB Share Document on Facebook

	Risk Factor Reduction Tool for Urinary Incontinence DocID: 1sNJS - View Document
	Urinary System and Your Health Drink water when you feel thirsty. Urinate often and when the urge arises. Consider limiting your caffeine intake. Green Flags — All Clear DocID: 1rcbV - View Document
	TrueNTH is a revolutionary new care intervention program that will help men living with prostate cancer to get access to life quality enhancing care and support including treatment information, lifestyle advice, experien DocID: 1qROp - View Document
	Microsoft PowerPoint - Q new Bowel and Bladder.ppt [Read-Only] [Compatibility Mode] DocID: 1q8pO - View Document
	A publication of the Urology Care Foundation extra UrologyHealth DocID: 1q7Ry - View Document